Replies to post #213089 on Biotech Values

[DewDiligence]

TCON starts phase-1b trial of TRC105+Opdivo in second-line NSCLC:

https://globenewswire.com/news-release/2017/11/29/1210620/0/en/TRACON-Doses-First-Patient-in-Phase-1b-Study-of-TRC105-with-Opdivo-in-Patients-with-Lung-Cancer.html

The Phase 1b clinical trial is an open-label, dose-escalation and expansion cohort study of TRC105 and Opdivo in patients with non-small cell lung cancer that have received prior chemotherapy. The primary objectives of the Phase 1b study are to assess the safety of TRC105 when given with Opdivo, determine its recommended Phase 2 dose with Opdivo and evaluate the response rate. The trial incorporates tumor biopsy testing to correlate tumor myeloid cell infiltration with response, in order to allow for potential biomarker-directed therapy of lung cancer patients.

The trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT03181308 .

[DewDiligence]

PFE—Phase-3 Inlyta trial in adjuvant RCC stopped for futility:

https://www.businesswire.com/news/home/20180410006316/en/

The trial tested Inlyta monotherapy vs placebo following surgical resection. The primary endpoint was DFS.